Hopefully correct, very good news. This patent could have been a complicating factor in reaching a deal with BMY or MRK or whomever as it gives NWBO the upper hand in the discussion, not the typical relationship when startup pharma works with BP. Think about the BMY situation, their flagship product, Opdivo, could be subordinated to the NWBO product in these discussions. However we do not know what combo filings BMY may have also done and who filed first if BMY did file, probably NWBO given their work with UCLA to bear out the claims. Very interesting news to be published.
News 
Market Data 
Discover 
AI
